International Journal of Hematology

GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating Diffuse Large B Cell Lymphoma

Retrieved on: 
星期四, 三月 28, 2024
B-cell lymphoma, Plasma, Shanghai Cancer Center, Rituximab, Apoptosis, Leukemia, International Journal of Hematology, Patient, Hospital, Doxorubicin, Vincristine, Fudan University, CC3, Standard of care, Acute myeloid leukemia, Epidemiology, Biomedical Chromatography, Prednisone, Peripheral T-cell lymphoma, PARP, National Cancer Center, Therapy, MYC, BTK, Safety, BeiGene, CDK9, Cyclophosphamide, DLBCL, Canadian International Council, MCL1, Follicular lymphoma, Pharmaceutical industry

The first patient was dosed in the trial led by prominent Henan Cancer Hospital and Fudan University Shanghai Cancer Center.

Key Points: 
  • The first patient was dosed in the trial led by prominent Henan Cancer Hospital and Fudan University Shanghai Cancer Center.
  • This study will be the first combination trial conducted by a Chinese biotech to combine CDK9 inhibitor and BTK inhibitor targeting DLBCL.
  • The trials of GFH009 treating peripheral T-cell lymphoma and acute myeloid leukemia have entered into phase II stage in China and the U.S. respectively.
  • Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020–2025, Leukemia & Lymphoma, 2021
    3.

Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin’s Lymphoma in Japan

Retrieved on: 
星期五, 十一月 18, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Marketing, Clinical trial, Lenalidomide, Engineering, Cancer, Lymphoma, Lymphocytosis, Safety, Risk, Independent Review Committee, Biotechnology, Respiratory tract, ORR, Orphan drug, Life, Research, Nature, Rituximab, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lymphoid leukemia, Intermittency, MEI, COVID-19, Waldenström's macroglobulinemia, Hope, LPL, Diarrhea, Patient, AST, International Journal of Hematology, FDA, Selinexor, Failure, Nephrology, ALT, Follicular lymphoma, Rash, SLL, ID, Kyowa Hakko Kirin, Neurology, Food, IRRC, Journal, Toxic leukoencephalopathy, TIDAL, Disclosure, Canadian International Council, Regulation, Colitis, DOR, TSE, Pharmaceutical industry, Fine chemical

We are very pleased to announce the data from Phase 2 MIRAGE study, said Yoshifumi Torii, Ph.D., Executive Officer, Vice President, Head of R&D Division of Kyowa Kirin.

Key Points: 
  • We are very pleased to announce the data from Phase 2 MIRAGE study, said Yoshifumi Torii, Ph.D., Executive Officer, Vice President, Head of R&D Division of Kyowa Kirin.
  • We remain committed to maximizing the value of zandelisib in B-cell malignancies with our partner MEI Pharma and bringing hope to lymphoma patients around the world.
  • In November 2021, MEI Pharma and Kyowa Kirin announced topline data from ongoing Phase 2 TIDAL study ( NCT03768505 ) evaluating zandelisib as a single agent for follicular lymphoma (FL) patients who received at least two prior systemic therapies.
  • MEI and Kyowa Kirin will co-develop and co-promote zandelisib in the U.S., with MEI booking all revenue from the U.S. sales.

Scopio Labs Launches Full-Field Peripheral Blood Smear Application, Bringing End-to-End Digital Workflow to Hematology Labs to Transform Diagnostic Testing

Retrieved on: 
星期一, 九月 27, 2021
Decision-making, International Journal of Hematology, RBC, Review, Diagnosis, Solution, FDA, Patient, Health, LinkedIn, Hospital, TEL, Canadian International Council, Twitter, CEO, Disease, CE, Research, Cell, X100, WBC, DSS, Medical imaging, Risk management, Medical device

Scopio Labs' FF-PBS application is the first end-to-end digital solution on the market that offers full-field imaging and an AI-powered Decision Support System (DSS) with true remote capabilities.

Key Points: 
  • Scopio Labs' FF-PBS application is the first end-to-end digital solution on the market that offers full-field imaging and an AI-powered Decision Support System (DSS) with true remote capabilities.
  • This unique approach streamlines labs' and clinicians' workflows and optimizes the blood smear analysis process.
  • Scopio's breakthrough imaging platformuses computational photography to provide unprecedented images of vast numbers of cells.
  • Scopio Labs has secured FDA clearance and CE approval for its Full-Field Peripheral Blood Smear Application and its ScopioVet application is already in commercial use across the U.S. and Europe.